Agios Pharmaceuticals AGIO Operating Lease Liability Payments - 2025 (Lessee)

Operating Lease Liability Payments - 2025 (Lessee) at other companies

PrecigenPGEN

——

BioCryst PharmaceuticalsBCRX

——

Aurinia PharmaceuticalsAUPH

——

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$20.7M+138%

Gross profit$19.4M+154%

Operating income-$110.0M-3.2%

Net income-$99.1M-11.0%

EPS (diluted)-$1.69-9.0%

Balance sheet

See full

Cash & equivalents$113.6M+43.9%

Total debt$35.7M-32.5%

Total equity$1.1B-24.4%

Total assets$1.2B-23.8%

Cash flow

See full

Operating cash flow-$118.9M-6.7%

CapEx$769.0K+0.4%

Free cash flow-$119.7M-6.6%

Valuation

See full

Market cap$2.12B+18.1%

Enterprise value$2.04B+15.2%

P/S32.1×-16.4×

Profitability

See full

Gross margin90%+2.5pp

Operating margin-720%-204pp

Net margin-639.8%—

FCF margin-582.5%-185pp

Returns & leverage

See full

Return on equity-32.8%—

Debt / equity0×0.0×

Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's operating lease liability payments - 2025 (lessee).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Agios Pharmaceuticals's operating lease liability payments - 2025 (lessee)?: Agios Pharmaceuticals (AGIO) reported operating lease liability payments - 2025 (lessee) of $3.48M in Q1 2026.
How has Agios Pharmaceuticals's operating lease liability payments - 2025 (lessee) changed year-over-year?: Agios Pharmaceuticals's operating lease liability payments - 2025 (lessee) decreased by 83.2% year-over-year, from $20.76M to $3.48M.